GlassScriptPhysician profile
Micha Abeles
NPI 1497751556
$19,037.91
in general payments reported to CMS, 2019-2025
34 companies · $3,217 in 2025
The $3,217 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $1,350 · 2021: $2,315 · 2022: $2,614 · 2023: $5,714 · 2024: $2,645 · 2025: $3,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,982 · Consulting Fee: $2,375 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,981.52 |
| Consulting Fee | $2,375.00 |
| Education | $219.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,024.45 | 2019-2023 | |
| Abbvie INC. | $2,904.10 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $2,461.84 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $2,038.43 | 2019-2025 | Evenity, Prolia, Enbrel |
| Janssen Biotech, INC. | $1,324.16 | 2019-2025 | Tremfya, Simponi, Remicade |
| Lilly USA, LLC | $1,049.81 | 2019-2025 | Taltz, Zepbound, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $761.82 | 2020-2025 | Orencia, Sotyktu |
| Radius Health, INC. | $719.37 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $650.88 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $648.93 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $641.03 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $449.37 | 2022-2025 | Lupkynis |
| Sobi, INC | $339.57 | 2019-2025 | |
| Genzyme Corporation | $332.19 | 2020-2025 | |
| Horizon Therapeutics Plc | $316.94 | 2022-2023 | Krystexxa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $294.25 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.44 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $139.96 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $136.83 | 2023-2024 | Idacio |
| Regeneron Healthcare Solutions, INC. | $119.41 | 2019 | |
| Organon LLC | $106.58 | 2021-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $75.09 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $52.22 | 2020-2021 | |
| Sandoz INC. | $42.86 | 2024-2025 | Hyrimoz |
| Kiniksa Pharmaceuticals, LTD. | $37.36 | 2023 | Arcalyst |
| Scilex Pharmaceuticals INC. | $34.60 | 2024 | |
| Mallinckrodt Enterprises LLC | $32.44 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $28.86 | 2024 | Arcalyst |
| Ani Pharmaceuticals, INC. | $24.61 | 2024 | Purified Cortrophin Gel |
| Almatica Pharma LLC | $22.22 | 2025 | Teriparatide |
| Gilead Sciences, INC. | $20.72 | 2020 | |
| Octapharma USA, INC. | $20.70 | 2024 | Octagam Immune Globulin (Human) |
| Actelion Pharmaceuticals US, INC. | $16.85 | 2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micha Abeles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.